Spine pain (SP), such as low back pain, is among the most common musculoskeletal disorders and is the single most common disorder causing disability in industrialized countries.
Recently, several genetic factors have been identified contributing to SP phenotypes and may serve as potential pharmaceutical targets. For example, common polymorphism in SCN9A, a gene encoding Nav1.7 channel, was associated with higher pain postdiscectomy.
7 Similarly, common allele in KCNS1 gene encoding for potassium channel subunit, were associated with pain severity in two different SP cohorts.
8 Therefore, manipulating these genes/alleles or modifying factors that interact with their effects on pain may lead to pain relief in patients with risk genotypes. Other genes may "protect" from SP, such as GCH1, a gene encoding GTP cyclohydrolase, a key enzyme for catecholamine, serotonin, and nitric oxide production.
9 Patients carrying two copies of "protective" allele may have better outcomes from spinal surgery in terms of chronic pain and functioning, so for them it becomes the treatment of choice.
Genetic approaches applied to SP research may help identify important molecular factors that may contribute to the risk for or protection against chronicity and recurrence. It is highly likely that the interactions among genes, psychosocial and psychophysical factors will shape SP experience.
10 Findings from human genetic association studies in painful conditions including SP and DDD have important clinical relevance and will eventually lead to personalized spine care. These will include "genetic signatures" of the risk for severe pain or pain chronification as well as patient's response to pain medicine.
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